Investigational drug · Phase 3
VER-01
Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Lumbosacral Radiculopathy, Chronic Non-specific Low Back Pain.
Phase 3Last checked: Nov 19, 2026Latest source record: Nov 17, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
2
1 still active
All registered trials
6
Any phase or sponsor naming "VER-01"
First trial start
2024
Jun 28, 2024
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "VER-01", any sponsor or status.
Conditions studied
As listed on its trial records.
- Lumbosacral Radiculopathy
- Chronic Non-specific Low Back Pain
Approved drugs for the same conditions: Pain and anesthesia
Largest trials
Live from ClinicalTrials.gov: studies naming "VER-01" as an intervention, largest first.
- Efficacy and Safety of VER-01 in the Treatment of Patients With Chronic Non-specific Low Back PainPivotal-lookingCompleted
Vertanical GmbHIndustry
NCT04940741 · 820 participants · Start Jul 7, 2021 · Primary completion Mar 26, 2024
Drug: VER-01 · For: Chronic Non-specific Low Back Pain
Sites: Berlin, Germany
- Efficacy and Safety of VER-01 in the Treatment of Participants With Chronic Painful Lumbosacral RadiculopathyPivotal-lookingRecruiting
Vertanical GmbHIndustry
NCT06956014 · 810 participants (planned) · Start Sep 22, 2026 · Primary completion Sep 2028
Drug: VER-01 · For: Lumbosacral Radiculopathy
Sites: Mobile, Alabama; Tempe, Arizona; Long Beach, California · 43 sites in all
- Dose-Response Characterization of VER-01 in the Treatment of Patients With Chronic Non-specific Low Back PainPivotal-lookingCompleted
Vertanical GmbHIndustry
NCT06475001 · 652 participants · Start Jun 28, 2024 · Primary completion Jul 31, 2025
Drug: VER-01; Placebo · For: Chronic Non-specific Low Back Pain
Sites: London, United Kingdom
- Comparison of VER-01 to Opioids in Patients With Chronic Non-specific Low Back PainPivotal-lookingCompleted
Vertanical GmbHIndustry
NCT05610813 · 384 participants · Start Jun 8, 2023 · Primary completion Oct 18, 2024
Drug: VER-01; Opioid therapy · For: Chronic Non-specific Low Back Pain
Sites: Bad Doberan, Germany; Hanover, Germany
Vertanical GmbHIndustry
NCT04930809 · 42 participants · Start Nov 25, 2021 · Primary completion Jul 4, 2022
Drug: VER-01 · For: Healthy
Sites: Vienna, Austria
Vertanical GmbHIndustry
NCT04930796 · 18 participants · Start Aug 10, 2022 · Primary completion Nov 17, 2022
Drug: VER-01 · For: Healthy
Sites: Vienna, Austria
Newest research
PubMed records naming it or its code names, newest first.
- Efficacy and Safety of Cannabinoid-Based Interventions for Low Back Pain and Migraine: A Systematic Review of Randomized Controlled Trials.
Costa-Oliveira CD, Castro MJ, Silvério LAL, et al. · Cannabis Cannabinoid Res 2026
- VER-01 Shows Enhanced Gastrointestinal Tolerability, Superior Pain Relief, and Improved Sleep Quality Compared to Opioids in Treating Chronic Low Back Pain: A Randomized Phase 3 Clinical Trial.
Meissner W, Argoff C, Sator S, et al. · Pain Ther 2025
- Full-spectrum extract from Cannabis sativa DKJ127 for chronic low back pain: a phase 3 randomized placebo-controlled trial.
Karst M, Meissner W, Sator S, et al. · Nat Med 2025
- Comparing the web-based and traditional self-reported 24-hour dietary recall data in the PakNutriStudy.
Tanweer A, Zia M, Riaz K, et al. · Comput Methods Programs Biomed 2023
Also in development for Lumbosacral Radiculopathy
- AFA-281Phase 22 trials
Afasci Inc · Alcohol Abuse, Alcohol Abuse/addiction, Anxiety
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.